There are several realities here. One, no one else has been able to produce Ofirmev. Second, while all of this legal mumbo jumbo goes on CADX can be cleaning up. This stuff can go on for years and years and meanwhile CADX gets to keep all the earnings, even if they have to spend a little on legal costs. If they win thelegal case this all goes away.
I couldn't agree more, long term this shouldn't be an issue. However I wonder if this news was baked into the price drop we have seen or if a new wave of volatility will hit. I've been so surprised in the past how differently people interpret news, for all I know the expectation was that the uspto was expected to reject all claims initially and the fact that they only rejected some could be a win. I agree this becomes a non issue with an excela win, I just don't want to be off the bandwagon when the announcement comes
First the earnings miss, then the very odd Bloomberg piece a week ago about adverse events w/oral Acetamin., and now this non-final patent non-event. The 30% s.p. drop in 2 weeks seems to point to some concentrated shorting by someone with 'asymmetrical information' (my favorite term of art) into the USPTO announcement well before today's release.